Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal

Lenalidomide is an effective component of induction and maintenance therapy for multiple myeloma, though with a risk of secondary malignancies, including acute lymphoblastic leukemia (ALL). In contrast to therapy-related myeloid neoplasia, lenalidomide-associated lymphoblastic neoplasia remains poor...

Descripción completa

Detalles Bibliográficos
Autores principales: Geyer, Mark B., Shaffer, Brian C., Bhatnagar, Bhavana, Mims, Alice S., Klein, Victoria, Dilip, Deepika, Glass, Jacob L., Lozanski, Gerard, Hassoun, Hani, Landau, Heather, Zhang, Yanming, Xiao, Wenbin, Roshal, Mikhail, Park, Jae H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362546/
https://www.ncbi.nlm.nih.gov/pubmed/36827680
http://dx.doi.org/10.1182/bloodadvances.2022009212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362546/
https://www.ncbi.nlm.nih.gov/pubmed/36827680
http://dx.doi.org/10.1182/bloodadvances.2022009212

Ejemplares similares